Accessibility Menu
 
Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

(NASDAQ) AUPH

Current Price$15.97
Market Cap$2.11B
Since IPO (2012)+675%
5 Year+25%
1 Year+110%
1 Month+8%

Aurinia Pharmaceuticals Financials at a Glance

Market Cap

$2.11B

Revenue (TTM)

$283.06M

Net Income (TTM)

$287.20M

EPS (TTM)

$2.08

P/E Ratio

7.65

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$15.97

Volume

20,065

Open

$15.89

Previous Close

$15.97

Daily Range

$15.78 - $16.12

52-Week Range

$7.15 - $16.54

AUPH: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aurinia Pharmaceuticals

Industry

Biotechnology

Employees

128

CEO

Peter S. Greenleaf, MBA

Headquarters

Edmonton, BC V8Z 7X8, CA

AUPH Financials

Key Financial Metrics (TTM)

Gross Margin

88%

Operating Margin

37%

Net Income Margin

1%

Return on Equity

60%

Return on Capital

16%

Return on Assets

38%

Earnings Yield

13.07%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.11B

Shares Outstanding

132.97M

Volume

20.07K

Short Interest

0.00%

Avg. Volume

1.06M

Financials (TTM)

Gross Profit

$250.39M

Operating Income

$104.91M

EBITDA

$127.76M

Operating Cash Flow

$135.66M

Capital Expenditure

$252.00K

Free Cash Flow

$135.41M

Cash & ST Invst.

$398.00M

Total Debt

$74.81M

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$77.11M

+28.8%

Gross Profit

$68.64M

+26.4%

Gross Margin

89.01%

N/A

Market Cap

$2.11B

N/A

Market Cap/Employee

$16.25M

N/A

Employees

130

N/A

Net Income

$210.79M

+14651.2%

EBITDA

$47.07M

+555.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$323.19M

+15.8%

Accounts Receivable

$41.45M

+13.4%

Inventory

$45.69M

+16.5%

Long Term Debt

$57.22M

-11.0%

Short Term Debt

$17.59M

+16.7%

Return on Assets

38.21%

N/A

Return on Invested Capital

15.95%

N/A

Free Cash Flow

$44.50M

+48.1%

Operating Cash Flow

$44.57M

+48.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STOKStoke Therapeutics, Inc.
$35.15+0.80%
CLDXCelldex Therapeutics, Inc.
$33.62+3.73%
HRMYHarmony Biosciences Holdings, Inc.
$29.16+2.42%
IMCRImmunocore Holdings plc
$31.81-0.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$61.72+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.45+0.02%
NOKNokia
$9.55+0.01%
PLTRPalantir Technologies
$130.49-0.07%

Questions About AUPH

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.